Xiamen Amoytop Biotech Co., Ltd.

Shanghai Stock Exchange 688278.SS

Xiamen Amoytop Biotech Co., Ltd. Receivables for the year ending December 31, 2023: USD 64.76 M

Xiamen Amoytop Biotech Co., Ltd. Receivables is USD 64.76 M for the year ending December 31, 2023, a 100.34% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Xiamen Amoytop Biotech Co., Ltd. Receivables for the year ending December 31, 2022 was USD 32.32 M, a -0.44% change year over year.
Xiamen Amoytop Biotech Co., Ltd. Receivables for the year ending December 31, 2021 was USD 32.46 M, a 14.54% change year over year.
Xiamen Amoytop Biotech Co., Ltd. Receivables for the year ending December 31, 2020 was USD 28.34 M, a 25.81% change year over year.
Xiamen Amoytop Biotech Co., Ltd. Receivables for the year ending December 31, 2019 was USD 22.53 M, a 1.68% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

Shanghai Stock Exchange: 688278.SS

Xiamen Amoytop Biotech Co., Ltd.

CEO	Mr. Li Sun
IPO Date	Jan. 17, 2020
Location	China
Headquarters	No. 330 Wengjiao Road
Employees	1,960
Sector	Healthcare
Industries Biotechnology Chemicals & Advanced Materials Cleaning Supplies Composite Materials Fertilizers Petrochemicals Pharmaceuticals Plastics

Description

Xiamen Amoytop Biotech Co., Ltd. engages in the manufacture, marketing, and sale of recombinant protein drugs using genetic engineering technology in China. It offers formulations, reagents, and APIs, as well as custom-manufacturing services. The company was founded in 1996 and is based in Xiamen, China.

Key trends

Past 5 years